Performance eradication of Staphylococcus aureus with mupirocin in nasal personnel ICU ward.

The efficacy of diagnosis and MRSA carriers therapy in the prevention of nosocomial infection in ICU department of 5th Azar Gorgan Hospital

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014102519666N1

Enrollment

240

Registered

2014-12-19

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Staphylococcus aureus infection. Staphylococcus aureus as the cause of diseases classified to other chapters

Interventions

mupirocin pomade 2% in nasal 2 times in day for 5 days.

Treatment - Drugs

mupirocin pomade 2% in nasal 2 times in day for 5 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients suffering from hospital infection with MRSA Staphylococcus aureus infection. Exclusion criteria: patients with kidney disease; dialysis; pregnancy and also sensitivity to drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Staphylococcus aureus. Timepoint: 3 month before and 3 month after intervention. Method of measurement: one coloni in culture & PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Khandandel

Golestan University of Medical Sciences

Ab.khandandel@gouma.ac.ir; ab.khandandel@gmail.com; ab.khandandel@yahoo.com+98 17 3222 0561

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026